| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer |
| Creator | Fabbro et al. |
| Author | Michel Fabbro |
| Author | Pierre-Emmanuel Colombo |
| Author | Cristina Marinella Leaha |
| Author | Philippe Rouanet |
| Author | Sébastien Carrère |
| Author | Marian Gutowski |
| Author | Anne Mourregot |
| Author | Véronique D'Hondt |
| Author | Isabelle Coupier |
| Author | Julie Vendrell |
| Author | Paul Vilquin |
| Author | Pascal Pujol |
| Author | Jérôme Solassol |
| Author | Caroline Mollevi |
| Abstract | Objective: High-grade serous ovarian cancers (HGSOC) are heterogeneous, often diagnosed at an advanced stage, and associated with poor overall survival (OS, 39% at five years). There are few data about the prognostic factors of late relapses in HGSOC patients who survived ?five years, long-term survivors (LTS). The aim of our study is to assess the probability of survival according to the already survived time from diagnosis. Methods: Data from HGSOC patients treated between 1995 and 2016 were retrospectively collected to estimate the conditional probability of survival (CPS), probability of surviving Y years after diagnosis when the patient had already survived X years, and to determine the LTS prognostic factors. The primary endpoint was OS. Results: 404 patients were included; 120 of them were LTS. Patients were aged 61 years (range: 20-89), WHO performance status 0-1 in 86.9% and 2 in 13.1%, and Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging III and IV in 82.7% and 17.3% patients. Breast cancer (BRCA) status was available in 116 patients (33% mutated), including 58 LTS (36% mutated). No macroscopic residual disease was observed in 58.4% patients. First-line platinum-based chemotherapy plus paclitaxel was administered in 80.4% of patients (median: six cycles (range: 1-14)). After a 9 point 3-year follow-up, median OS was four years (95% CI: 3.6-4.5). The CPS at five years after surviving one year was 42.8% (95% CI: 35.3-48.3); it increased to 81.7% (95% CI: 75.5-87.8) after four survived years. Progression-free interval>18 months was the only LTS prognostic factor in the multivariable analysis (hazard ratio (HR) = 0.23; 95% CI: 0.13-0.40; p < 0.001). Conclusion: The CPS provided relevant and encouraging clinical information on the life expectancy of HGSOC patients who already survived a period of time after diagnosis. LTS prognostic factors are useful for clinicians and patients. |
| Publication | Cancers |
| Volume | 12 |
| Issue | 8 |
| Pages | 2184 |
| Date | 2020-08-05 |
| Journal Abbr | Cancers (Basel) |
| Language | eng |
| DOI | 10.3390/cancers12082184 |
| ISSN | 2072-6694 |
| Library Catalog | PubMed |
| Extra | PMID: 32764409 PMCID: PMC7465919 |
| Tags | clinic, conditional probability of survival, high-grade serous ovarian cancer, long-term survival |
| Date Added | 2023/11/14 - 15:24:04 |
| Date Modified | 2023/11/14 - 15:43:24 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
